During this hour-long panel discussion, we explored the variation of perception of what is most critical for the patient during the drug development process. From a range of perspectives we discussed the elements that are controversial and most challenging, especially in extremely novel and innovative interventions.
- Gilbert Wagener, Senior Vice President & Chief Medical Officer at Ixaka
- Nicholas Johnson, Chief Strategy and Impact Officer at Cell and Gene Therapy Catapult
- Sandy Douglas, Research Group Leader at Jenner Institute
- Wills Hughes-Wilson, Chief Patient Access & Commercial Planning at Mereo BioPharma